Cardinal Health Releases New Smart Thermometer Technology; Alaris Tri-Site Thermometer Integrates Smart 'Adaptive' Algorithm and Dual Probe Configuration for Improved Clinical Efficiency.

SAN DIEGO -- Cardinal Health, Inc. (NYSE:CAH), a leading provider of products and services supporting the health care industry, announced today the release of the Alaris(R) Tri-Site Thermometer, an innovative new tool for temperature measurement. The Alaris(R) Tri-Site Thermometer features a new smart "adaptive" algorithm that adjusts to the heat transfer characteristics of the appropriate body site, thus providing fast and reliable temperature predictions without dependence on the patient's age.

The Alaris(R) Tri-Site Thermometer comes standard with backlight, pulse timer, anti-theft protection, long cords and a three-year limited warranty. Additionally, Cardinal Health offers the Alaris(R) Tri-Site Thermometer as dual integrated probes for environments where oral, axillary or rectal measurement decisions often occur at the bedside. Only Cardinal Health offers an integrated dual probe design.

Since 1971, Cardinal Health has been partnering with healthcare professionals worldwide to provide electronic thermometry solutions. Worldwide over 1,000,000 temperatures a day are taken with Cardinal Health thermometers.

About Cardinal Health

Cardinal Health, Inc. (www.cardinalhealth.com) is the leading provider of products and services supporting the health care industry. Cardinal Health develops, manufactures, packages and markets products for patient care; develops drug-delivery technologies; distributes pharmaceuticals and medical, surgical and laboratory supplies; and offers consulting and other services that improve quality and efficiency in health care. Headquartered in Dublin, Ohio, Cardinal Health employs more than 55,000 people on six continents and produces annual revenues of more than $65 billion.

Except for historical information, all other information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Cardinal Health's Form 10-K, Form 8-K and Form 10-Q reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the costs, difficulties, and uncertainties related to the integration of acquired businesses, the loss of one or more key customer or supplier relationships or changes to the terms of those relationships, changes in the distribution patterns or reimbursement rates for health-care products and/or services, the results, consequences, effects or timing of any inquiry or investigation by any regulatory authority or any legal and administrative proceedings, the impact of previously announced restatements, difficulties in opening new facilities or fully utilizing existing capacity, difficulties and uncertainties associated with business model transitions, including the conversion of margin generated from branded pharmaceutical manufacturers to non-contingent consideration, and general economic and market conditions. Cardinal Health undertakes no obligation to update or revise any forward-looking statement.